Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159595 | 0.78 | ALDH1A1 (0.39) | MGAMGAASIMGAM2KDM4E | |
| SCHEMBL1491066 | 0.78 | KDM4E (0.32) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL5325880 | 0.77 | KDM4E (0.31) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL315476 | 0.77 | MAPT (0.33) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL8012068 | 0.77 | KDM4E (0.31) | MGAMGAASIMGAM2KDM4E | |
| SCHEMBL27849022 | 0.75 | CA2 (0.34) | MGAMGAASIMGAM2KDM4E | |
| SCHEMBL1299017 | 0.75 | MGAM (0.37) | MGAMGAASIMGAM2KDM4E | |
| SCHEMBL16974713 | 0.75 | ALDH1A1 (0.33) | MGAMGAASIMGAM2KDM4E | |
| SCHEMBL2347090 | 0.71 | — | — | |
| SCHEMBL719277 | 0.71 | ALDH1A1 (0.37) | TAS1R3TAS1R1TAS1R2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080088-B1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2019-07-31 | — | — | EP | claimed |
| EP-3080088-B1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2019-07-31 | — | — | EP | disclosed |
| US-9815791-B2 | Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160304465-A1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-10-20 | — | — | US | disclosed |
| CN-101115723-B | Pyrazole carboxylic acid anilides, method for the production thereof and agents containing them for controlling pathogenic fungi | BASF AG (DE) | 2012-02-22 | — | — | CN | disclosed |
| US-8008232-B2 | Such as N-(3',4'-dichlorobiphenyl-2-yl)-5-chloro-1,3-dimethyl-1H-pyrazole-4-carboxamide; seeds | BASF AKTIENGESELLSCHAFT (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | BASF AKITENGESELLSCHAFT (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101115723-A | Pyrazole carboxylic acid anilides, method for the production thereof and agents containing them for controlling pathogenic fungi | BASF AG (DE) | 2008-01-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | CBR3, C1S, PYM1 | PTGS2 3961/4885TAS1R3 2128/4885TAS1R1 3036/4885 |
| US-20160304465-A1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | PTGS2 872/4885TAS1R3 4161/4885TAS1R1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.